Eric P. Krenning
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2025
Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 30, 2024
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile.
Journal: International journal of molecular sciences
Published: December 28, 2023
Side-Chain Modified [99mTc]Tc-DT1 Mimics: A Comparative Study in NTS1R-Positive Models.
Journal: International journal of molecular sciences
Published: October 07, 2023
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours.
Journal: Journal of neuroendocrinology
Published: July 14, 2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 25, 2021
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Journal: Purinergic signalling
Published: January 20, 2021
Last Updated: 09/26/2026